Bounded by design
Limit sources, tools, actions, and user scope to the intended use case.
Trust comes from clear boundaries, visible evidence, controlled change, and named human ownership—not a general promise that AI is safe.
Every AI Pharma implementation should be able to answer who can use the system, what information it can access, what action it can take, who reviews the result, and what happens when the system is uncertain or fails.
Limit sources, tools, actions, and user scope to the intended use case.
Connect outputs to evidence, configuration, model, workflow, and review information.
Provide enough context for a qualified person to verify, revise, reject, or escalate.
Manage access, changes, incidents, retention, and periodic re-evaluation as part of the service.
Data controls are agreed before ingestion. We document the source, purpose, permitted users, retention period, deployment location, and deletion or return process for each relevant data class.
Use approved corpora, document owners, revision status, licences, and access classifications.
Carry user permissions through retrieval and actions; do not rely on a generic shared identity.
Collect and retain only what the workflow requires, with a documented lifecycle.
Keep tenant, environment, development, evaluation, and production boundaries explicit.
Data residency is a design input. A deployment region is only one part of the boundary; service providers, subprocessors, telemetry, support access, and integrations also need to be considered.
Security requirements depend on the data, environment, integration, and operating model. The design should cover identity, network, storage, application, model supply chain, secrets, monitoring, and incident response.
AI governance is an operating discipline. It connects intended use, risk, evaluation, approval, deployment, monitoring, change control, incidents, and retirement.
Version prompts, models, retrieval indexes, tools, policies, and interface changes as a connected release.
Name the business owner, technical owner, reviewer, and escalation path for the workflow.
Define which changes require focused regression testing, full re-evaluation, or formal approval.
Plan how access, data, integrations, retained records, and open actions are handled when a system ends.
Trust is maintained through recurring work: access review, source verification, monitoring, feedback review, incident exercises, and re-evaluation as the model, workflow, or environment changes.
Failures, latency, source access, anomalous use, escalation, and reviewer outcomes.
Sampled outputs, corrections, missed sources, disagreement, and emerging edge cases.
Convert findings into test cases, documentation updates, training, or workflow changes.
“GxP-aware” means the delivery method recognises regulated processes, documentation, review, and change control. It does not mean a generic AI system is automatically compliant or approved for every regulated use.
Requirements may include validated systems, electronic records and signatures, electronic systems and records controls, privacy and security obligations, sector-specific requirements, and customer quality agreements. These should be assessed and documented for the actual system.
Need a due-diligence pack? Contact us with your quality, security, privacy, and intended-use requirements so the appropriate evidence can be scoped.
We will help separate what the platform can support from what requires customer-specific validation, process change, or a qualified system owner.